Opinion|Videos|November 27, 2024
Challenges of BCG-Unresponsive NMIBC
Author(s)Katie S. Murray, DO, MS
Key Takeaways
- BCG therapy resistance in bladder cancer patients is influenced by tumor biology, immune variability, and genetic factors, impacting prognosis negatively.
- Non-responders to BCG therapy often require alternative treatments, facing a poorer prognosis compared to responders.
Katie S. Murray, DO, discusses why some patients do not respond to BCG therapy, exploring factors such as tumor biology and immune system dysfunction, and how this impacts their prognosis, while also addressing the challenges and unmet needs in treating these patients, including the current BCG shortages and how it is reshaping treatment approaches.
Advertisement
Episodes in this series
- Why do some patients not respond to BCG therapy and how may it impact their prognosis?
- What challenges or unmet needs do you face when treating these patients?
- Discuss your thoughts and opinions on the current BCG shortages. How is this changing how you are managing your patients?
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
Patient Selection and Partnership in Prostate Radiotherapy Spacing
3
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
4
Alternative BCG strains may help address ongoing supply challenges in NMIBC
5